Burnsil

Each gram contains: Silver Sulfadiazine USP 10 mg/g (1% w/w).

Silver Sulfadiazine is a local chemotherapeutic for prevention and treatment of burn wound infections. Silver Sulfadiazine disintegrates in the burn wound, thereby causing a slow and sustained release of silver ions. Silver ions bind to bacterial deoxyribonucleic acid, thus inhibiting the growth and multiplication of bacterial cells without affecting the cells of the skin and subcutaneous tissue. Silver sulfadiazine cream has a broad antibacterial spectrum including virtually all microbial species likely to infect the burn wound: Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, strains of Proteus and Klebsiella; it is also effective against Candida albicans and other fungi. Silver Sulfadiazine cream penetrates into the necrotic tissue and exudate. This effect is very important in view of the fact that systemic antibiotics are not effective against the bacterial flora of vascular burn necrosis.

Treatment of infected burn wounds.
Prevention of infection of burn wounds.
Treatment of infected skin lesions.

Mode of Application: Silver sulfadiazine can be applied directly to the wound in a layer of at least 2-3 mm. It can also be applied using a sterile gauze dressing. At least every 24 hours the cream should be reapplied after removal of the old cream. Application is easy and painless. Discoloration of linen and bed clothes does not occur.

The use of Silver Sulfadiazine is contraindicated in premature infants and neonates because of possible kernicterus. Silver Sulfadiazine should not be used in pregnancy, except in cases when the potentially life-saving benefits of the medication outweigh possible hazard to the fetus. Sensitization by silver sulfadiazine has not been reported in clinical studies. Only on theoretical grounds should attention be paid to the following possible contraindications of sulfonamides: hypersensitivity, liver damage and oliguria.

Under the influence of sunlight, a grayish discoloration of the cream may occur. It is therefore advised not to expose silver sulfadiazine treated body parts to direct sunlight.

Leucopenia has been reported in a restricted number of patients (incidence 0.4%). In most of these patients the white blood cell count (WBC) returned to normal in spite of prolonged treatment. In case signs or symptoms possibly related to leucopenia appear or when the patient is known to be hypersensitive to sulfonamides, a WBC count is recommended. Skin rash has been reported in a small number of patients (incidence 0.3%), but appears to be related to excipients propylene glycol and cetyl alcohol. Silver sulfadiazine has not been shown to alter electrolyte balance.

Store at temperatures not exceeding 30°C. Protect from light.

Topical Antibiotics

D06BA01 - silver sulfadiazine ; Belongs to the class of topical sulfonamides used in the treatment of dermatological diseases.

Rx